3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Interventions
Oxaliplatin
21
Capecitabine
17
Fluorouracil
15
Irinotecan
11
Radiotherapy
10
Leucovorin
8
Cetuximab
6
Bevacizumab
6
Gemcitabine
5
oblimersen
3
fludarabine
3
aldesleukin
3
Nivolumab
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
labetuzumab
2
dehydroftorafur
2
conatumumab
2
Tomography, X-Ray Computed
2
Receptor Protein-Tyrosine Kinases
2
Radiation
2
Panitumumab
2
Neoadjuvant Therapy
2
Magnetic Resonance Imaging
2
Interleukin-2
2
Gefitinib
2
Electrocardiography
2
Diphenhydramine
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rectal Neoplasms
×
Mastectomy, Segmental
×
Clear all
NCT06395337
2024-05-02
MIRCA & MIPAC
Radboud University Medical Center
Phase 1/2
Unknown
20 enrolled